GRC-6211

GRC-6211 is a drug developed by Glenmark Pharmaceuticals which acts as a potent and selective antagonist for the TRPV1 receptor. It has analgesic and antiinflammatory effects and reached Phase IIb human trials, but was ultimately discontinued from development as a medicine, though it continues to have applications in scientific research.^[1][2][3]

GRC-6211

Identifiers
IUPAC name 1-[(4R)-6-fluorospiro[3,4-dihydrochromene-2,1'-cyclobutane]-4-yl]-3-isoquinolin-5-ylurea
CAS Number	1166398-35-1
PubChem CID	138393987
ChemSpider	81367687
UNII	4S841S9BO9
Chemical and physical data
Formula	C22H20FN3O2
Molar mass	377.419 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC2(C1)C[C@H](C3=C(O2)C=CC(=C3)F)NC(=O)NC4=CC=CC5=C4C=CN=C5
InChI InChI=1S/C22H20FN3O2/c23-15-5-6-20-17(11-15)19(12-22(28-20)8-2-9-22)26-21(27)25-18-4-1-3-14-13-24-10-7-16(14)18/h1,3-7,10-11,13,19H,2,8-9,12H2,(H2,25,26,27)/t19-/m1/s1 Key:JADKHWDNSKIILG-LJQANCHMSA-N